History of Botulinum Toxin Treatment in Movement Disorders

Jabbari, Bahman

doi:10.5334/tohm.321

Cited by 42 publications

(29 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BoNT/A is a highly potent neurotoxin that has been in medical use for several decades in the treatment of localized motor dysfunction and muscle spasms such as blepharospasm, cervical dystonia, strabism, and hemifacial spasm [153]. Beyond motor/movement disorders, also treatment of autonomic dysfunction such as sialorrhea, hyperhidrosis, and detrusor overactivity using BoNT/A injections has been explored.…”

Section: Botulinum Neurotoxin a Intradetrusor Injectionsmentioning

confidence: 99%

The Management of Urine Storage Dysfunction in the Neurological Patient

Mehnert

2018

SN Compr. Clin. Med.

View full text Add to dashboard Cite

To highlight the current aspects and developments in the management of neurogenic urine storage dysfunction and to sensitize urologists for this interdisciplinary and important topic. Neurogenic lower urinary tract dysfunction affects a large proportion of patients with chronic neurological diseases or lesions such as multiple sclerosis, Parkinson's disease, stroke, spina bifida, and spinal cord injury. Such a dysfunction is not only highly bothersome and devastating for the quality of life but also poses a significant risk for health. Particularly, detrusor overactivity and detrusor-sphincterdyssynergia are frequent pathological patterns in neurogenic lower urinary tract dysfunction that are associated with sequelae such as recurrent urinary tract infections and renal impairment. The current cornerstones of treatment for urine storage dysfunction in neurological patients such as intermittent self-catheterization, antimuscarinic drugs, botulinum neurotoxin A intradetrusor injections, augmentation cystoplasty, urinary diversion, and artificial urinary sphincter have significantly contributed to improvements in QoL, health, and survival of neurological patients affected by neurogenic lower urinary tract dysfunction. However, these treatments have not advanced much recently. Moreover, the level of evidence of many therapy options specifically regarding their application in neurological patients is quite low and the main and auxiliary mechanisms of action are often only poorly understood. Despite former accomplishments in Neuro-Urology, more specific evidence for treatments of lower urinary tract dysfunction in neurological patients as well as better knowledge on their mechanisms of action is needed to advance the field and exploit the full treatment potential of available therapies.

show abstract

Section: Botulinum Neurotoxin a Intradetrusor Injectionsmentioning

confidence: 99%

The Management of Urine Storage Dysfunction in the Neurological Patient

Mehnert

2018

SN Compr. Clin. Med.

View full text Add to dashboard Cite

show abstract

“…The injected BTX-A dose ranged from 1.25 to 300 U of onabotulinumtoxinA. The reported indications were cervical dystonia (9 patients), strabismus (2), blepharospasm (2), limb dystonia (1), oromandibular dystonia (1), and spasmodic dysphonia (1). A total of 19 fetuses from 18 pregnancies (one twin pregnancy) were exposed to BTX-A in utero.…”

Section: Review Of the Physician Survey Regarding Therapeutic Btx-a Amentioning

confidence: 99%

“…Botulinum toxin is considered one of the most potent normally occurring toxin produced by Clostridium botulinum bacteria, which is able to block the neuromuscular transmission by binding to the motor or sympathetic nerve terminals and inhibiting the release of acetylcholine causing partial chemical denervation of the muscle resulting in a localized reduction in muscle activity [1][2][3]. Botulinum toxin has eight serotypes (A to H), both type A and B are the only used in the clinical practice.…”

Section: Introductionmentioning

confidence: 99%

“…Botulinum toxin has eight serotypes (A to H), both type A and B are the only used in the clinical practice. Type A toxins are Botox® (onabotulinumtoxinA), Xeomin® (incobotulinumtoxinA), and Dysport® (abobotulinumtoxinA) while type B toxin is Myobloc® (rimabotulinumtoxinB) [1]. Botulinum toxin type A (BTX-A) has been used for injection in the treatment of several medical disorders and cosmetic purposes; strabismus, blepharospasm, hemifacial spasm (HFS) cervical dystonia (CD), hyperactive bladder, sialorrhea, hyperhidrosis, migraine, spasticity and to improve wrinkle appearance [1,3], while botulinum toxin type B (BTX-B) is usually spared for conditions which are refractory to BTX-A [4].…”

Section: Introductionmentioning

confidence: 99%

“…Type A toxins are Botox® (onabotulinumtoxinA), Xeomin® (incobotulinumtoxinA), and Dysport® (abobotulinumtoxinA) while type B toxin is Myobloc® (rimabotulinumtoxinB) [1]. Botulinum toxin type A (BTX-A) has been used for injection in the treatment of several medical disorders and cosmetic purposes; strabismus, blepharospasm, hemifacial spasm (HFS) cervical dystonia (CD), hyperactive bladder, sialorrhea, hyperhidrosis, migraine, spasticity and to improve wrinkle appearance [1,3], while botulinum toxin type B (BTX-B) is usually spared for conditions which are refractory to BTX-A [4]. Given that approximately half of all pregnancies are unplanned and the increased use of BTX-A in the management of women of reproductive age, the incidental exposure of pregnant women to the drug became more common [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pregnancy outcomes following botulinum toxin type A exposure: A systematic review

Abdelkader

Arslan

Coskun

et al. 2018

int.jour.sci.res.mana

View full text Add to dashboard Cite

Objective: To evaluate the available human data to-date in order to assess whether the prenatal exposure to botulinum toxin type A (BTX-A) is associated with major congenital malformations and other adverse pregnancy outcomes. Methods: Searches were conducted in PubMed/MEDLINE and Reprotox in November 2017. Cohort and case-control studies, case series, case reports were the primary data of interest. Results: No controlled studies but case series and case reports of therapeutic BTX-A administration during pregnancy were identified. Case reports regarding pregnant women with botulism were also reviewed. Conclusions: Limited data suggests that BTX-A exposure for therapeutic indications during pregnancy does not seem to be associated with an increase in risk of major congenital malformations. Rates of fetal loss were substantially different between prospective and retrospective data. Controlled epidemiological studies are needed to refute or support our findings.

show abstract

Botulinum toxin: State of the art

2017

View full text Add to dashboard Cite

Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. © 2017 International Parkinson and Movement Disorder Society.

show abstract

History of Botulinum Toxin Treatment in Movement Disorders

Cited by 42 publications

References 41 publications

The Management of Urine Storage Dysfunction in the Neurological Patient

The Management of Urine Storage Dysfunction in the Neurological Patient

Pregnancy outcomes following botulinum toxin type A exposure: A systematic review

Botulinum toxin: State of the art

Contact Info

Product

Resources

About